JP2009545313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009545313A5 JP2009545313A5 JP2009522733A JP2009522733A JP2009545313A5 JP 2009545313 A5 JP2009545313 A5 JP 2009545313A5 JP 2009522733 A JP2009522733 A JP 2009522733A JP 2009522733 A JP2009522733 A JP 2009522733A JP 2009545313 A5 JP2009545313 A5 JP 2009545313A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- muscle
- sequence
- disease
- terminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 108020001507 fusion proteins Proteins 0.000 claims 14
- 102000037865 fusion proteins Human genes 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 11
- 210000004899 c-terminal region Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 108010056852 Myostatin Proteins 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 7
- 230000001575 pathological effect Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 102000004472 Myostatin Human genes 0.000 claims 5
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- 229920002704 polyhistidine Polymers 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 4
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 208000029549 Muscle injury Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000008468 bone growth Effects 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 208000001076 sarcopenia Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000026072 Motor neurone disease Diseases 0.000 claims 2
- 206010028311 Muscle hypertrophy Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000009815 adipogenic differentiation Effects 0.000 claims 2
- 210000000577 adipose tissue Anatomy 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000018678 bone mineralization Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000020411 cell activation Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 238000001976 enzyme digestion Methods 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 208000007903 liver failure Diseases 0.000 claims 2
- 231100000835 liver failure Toxicity 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 230000037257 muscle growth Effects 0.000 claims 2
- 230000012042 muscle hypertrophy Effects 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 210000003098 myoblast Anatomy 0.000 claims 2
- 230000012107 myoblast migration Effects 0.000 claims 2
- 208000013315 neuromuscular junction disease Diseases 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 108091008146 restriction endonucleases Proteins 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000282994 Cervidae Species 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 102000007474 Multiprotein Complexes Human genes 0.000 claims 1
- 108010085220 Multiprotein Complexes Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 238000012408 PCR amplification Methods 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000286209 Phasianidae Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83552506P | 2006-08-03 | 2006-08-03 | |
| PCT/NZ2007/000203 WO2008016314A1 (en) | 2006-08-03 | 2007-08-02 | Myostatin antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201653A Division JP5993827B2 (ja) | 2006-08-03 | 2013-09-27 | ミオスタチンアンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009545313A JP2009545313A (ja) | 2009-12-24 |
| JP2009545313A5 true JP2009545313A5 (enExample) | 2010-10-14 |
Family
ID=38997428
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522733A Pending JP2009545313A (ja) | 2006-08-03 | 2007-08-02 | ミオスタチンアンタゴニスト |
| JP2013201653A Expired - Fee Related JP5993827B2 (ja) | 2006-08-03 | 2013-09-27 | ミオスタチンアンタゴニスト |
| JP2016074671A Withdrawn JP2016130251A (ja) | 2006-08-03 | 2016-04-01 | ミオスタチンアンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013201653A Expired - Fee Related JP5993827B2 (ja) | 2006-08-03 | 2013-09-27 | ミオスタチンアンタゴニスト |
| JP2016074671A Withdrawn JP2016130251A (ja) | 2006-08-03 | 2016-04-01 | ミオスタチンアンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8309068B2 (enExample) |
| EP (1) | EP2054434B1 (enExample) |
| JP (3) | JP2009545313A (enExample) |
| CN (1) | CN101522707B (enExample) |
| AU (1) | AU2007279456A1 (enExample) |
| BR (1) | BRPI0715072A2 (enExample) |
| CA (1) | CA2693378C (enExample) |
| DK (1) | DK2054434T3 (enExample) |
| WO (1) | WO2008016314A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080118487A1 (en) * | 2004-09-30 | 2008-05-22 | Orico Limited | Myostatin Isoform |
| CA2993053A1 (en) * | 2009-04-27 | 2010-11-04 | Novartis Ag | Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth |
| CN101659700B (zh) * | 2009-07-27 | 2011-11-16 | 广州罗森生物科技有限公司 | 一种短肽 |
| WO2011040823A1 (en) * | 2009-10-01 | 2011-04-07 | Covita Limited | Synthetic myostatin peptide antagonists |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| CA2808382A1 (en) * | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| JP6177249B2 (ja) | 2011-11-14 | 2017-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法 |
| US10307480B2 (en) * | 2014-11-06 | 2019-06-04 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| PT3922645T (pt) | 2015-09-15 | 2025-05-29 | Scholar Rock Inc | ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| US11566047B2 (en) | 2016-08-10 | 2023-01-31 | Tokyo University Of Pharmacy & Life Sciences | Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof |
| US11155611B2 (en) * | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
| KR20200128125A (ko) | 2018-03-01 | 2020-11-11 | 리제너론 파아마슈티컬스, 인크. | 신체 조성을 변경하기 위한 방법 |
| CN111902157B (zh) * | 2018-03-21 | 2023-08-04 | 松阳生技股份有限公司 | 促进局部肌肉增长、减缓或防止局部肌肉萎缩的组合物及其用途 |
| TWI649332B (zh) | 2018-03-21 | 2019-02-01 | 英屬安圭拉商維多利亞生物醫學控股股份有限公司 | Composition for promoting local muscle growth, slowing or preventing local muscle atrophy and use thereof |
| CN112384247B (zh) * | 2018-07-02 | 2024-09-27 | 库拉米斯公司 | 利用细胞融合技术的基因及细胞治疗剂以及其的用途 |
| US20220119489A1 (en) * | 2019-01-25 | 2022-04-21 | Children's Medical Center Corporation | Compositions and methods for treating muscular dystrophy and related disorders |
| US20220331290A1 (en) * | 2019-09-24 | 2022-10-20 | Myo-Tec-Sci | Pharmaceutical composition for preventing or treating sarcopenia, containing unnatural amino acid |
| WO2022119367A1 (ko) * | 2020-12-03 | 2022-06-09 | ㈜라트바이오 | 마이오스타틴 유전자가 변형된 형질전환 동물 |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| CN120192396A (zh) * | 2023-12-21 | 2025-06-24 | 江苏省农业科学院 | 一种肌肉生长抑制素mstn蛋白突变体及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5874409A (en) * | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| SK722002A3 (en) | 1999-07-20 | 2003-02-04 | Pharmexa As | Method for down-regulating GDF-8 activity |
| US7368534B2 (en) | 2000-01-18 | 2008-05-06 | Orico Limited | Myostatin and mimetics thereof |
| CA2484941A1 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| EP1578928B1 (en) | 2002-09-16 | 2010-03-17 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| NZ529860A (en) * | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
| CN1902221A (zh) | 2003-12-31 | 2007-01-24 | 先灵-普劳有限公司 | 基于中和表位的生长增强疫苗 |
| MX2007000976A (es) * | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US20070190056A1 (en) * | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
-
2007
- 2007-08-02 CA CA2693378A patent/CA2693378C/en not_active Expired - Fee Related
- 2007-08-02 DK DK07834817.4T patent/DK2054434T3/en active
- 2007-08-02 CN CN2007800366228A patent/CN101522707B/zh not_active Expired - Fee Related
- 2007-08-02 JP JP2009522733A patent/JP2009545313A/ja active Pending
- 2007-08-02 US US12/376,289 patent/US8309068B2/en not_active Expired - Fee Related
- 2007-08-02 EP EP07834817.4A patent/EP2054434B1/en not_active Not-in-force
- 2007-08-02 WO PCT/NZ2007/000203 patent/WO2008016314A1/en not_active Ceased
- 2007-08-02 BR BRPI0715072-5A patent/BRPI0715072A2/pt not_active Application Discontinuation
- 2007-08-02 AU AU2007279456A patent/AU2007279456A1/en not_active Abandoned
-
2013
- 2013-09-27 JP JP2013201653A patent/JP5993827B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-01 JP JP2016074671A patent/JP2016130251A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200325200A1 (en) | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) | |
| TWI427084B (zh) | 穩定化之類胰島素生長因子多肽 | |
| JP2009515529A5 (enExample) | ||
| JP2008500373A5 (enExample) | ||
| KR20230169417A (ko) | Gdf15 융합 단백질 및 이의 용도 | |
| JPH10502527A (ja) | ＴＧＦ−βファミリーの新規な成長／分化因子 | |
| KR20180056628A (ko) | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 | |
| CN102741276A (zh) | 合成的肌肉抑制素肽拮抗剂 | |
| JP2021075550A (ja) | グルカゴン類似ペプチド−１受容体亢進剤を含む筋減少症治療用薬学組成物 | |
| CN1202112A (zh) | 增强胰腺功能的组合物 | |
| JP2009510999A (ja) | キメラ治療剤 | |
| US20260048102A1 (en) | Immunomodulatory compositions and methods | |
| KR20090118078A (ko) | 척수 손상 치료제 | |
| JP2023116739A (ja) | Ａｐｏｃ－ｉｉ模倣ペプチド | |
| EP3694537A1 (en) | Combination therapy for treatment of bone disorders | |
| JPH06508984A (ja) | ヒトのガラニン、ヒトのガラニンをエンコードするｃＤ ＮＡクローンとヒトのガラニン製造方法 | |
| CN1288754A (zh) | 提高饲料效率和家畜生长速度的基因处理 | |
| EP3010524B1 (en) | Protamine in treatment of neuronal injuries | |
| CN104379161A (zh) | 促进血管生长的蛋白质及其用途 | |
| JP4520951B2 (ja) | インスリン分泌誘導剤及びインスリン分泌誘導組成物 | |
| JP6094485B2 (ja) | ビリルビン排泄促進剤 | |
| KR20180027924A (ko) | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 | |
| JP2007238487A (ja) | 脊髄損傷に対する嗅粘膜移植にｈｇｆを用いた神経機能再建法 | |
| KR20180124816A (ko) | 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물 | |
| JP2025540675A (ja) | オクタデカニューロペプチド（ｏｄｎ）およびその合成誘導体を含む組成物、ならびに食物摂取、肥満、体重、吐き気および嘔吐の調節のための使用方法 |